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Abstract
Background: Vitamin D serum levels have been found to be related to sun exposure and diet, together with cell
differentiation, growth control and consequently, cancer risk. Vitamin D receptor (VDR) genotypes may influence cancer
risk; however, no epidemiological studies in sporadic breast cancer (BC) or malignant melanoma (MM) have been
performed in a southern European population. In this study, the VDR gene has been evaluated in two epithelial cancers
BC and MM.
Methods: We have conducted an analysis in 549 consecutive and non-related sporadic BC cases and 556 controls, all
from the Spanish population, and 283 MM cases and 245 controls. Genotyping analyses were carried out on four
putatively functional SNPs within the VDR gene.
Results: An association with the minor allele A of the non-synonymous SNP rs2228570 (rs10735810, FokI, Met1Thr)
was observed for BC, with an estimated odds ratio (OR) of 1.26 (95% CI = 1.02–1.57; p = 0.036). The synonymous
variant rs731236 (TaqI) appeared to be associated with protection from BC (OR = 0.80, 95%CI = 0.64–0.99; p = 0.047).
No statistically significant associations with MM were observed for any SNP. Nevertheless, sub-group analyses revealed
an association between rs2228570 (FokI) and absence of childhood sunburns (OR = 0.65, p = 0.003), between the 3'utr
SNP rs739837 (BglI) and fair skin (OR = 1.31, p = 0.048), and between the promoter SNP rs4516035 and the more
aggressive tumour location in head-neck and trunk (OR = 1.54, p = 0.020).
Conclusion: In summary, we observed associations between SNPs in the VDR gene and BC risk, and a comprehensive
analysis using clinical and tumour characteristics as outcome variables has revealed potential associations with MM. These
associations required confirmation in independent studies.
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Background
The vitamin D metabolite 1α,25-dihydroxivitamin D3
(1,25D, also known as calcitriol) is the biologically active
form of vitamin D3 [1]. The concentration of vitamin D3
in natural foods is quite low, and the majority of vitamin
D3 in individuals is from cholesterol metabolites in the
skin upon exposure to ultraviolet (UV) radiation. 1,25D
modulates the expression of specific genes in a tissue-spe-
cific manner by binding to the nuclear vitamin D receptor
(VDR) and to specific DNA vitamin D response elements.
The receptor and ligand induce a program of gene expres-
sion that contributes to the maintenance of the quiescent,
differentiated phenotype. They are therefore able to regu-
late cellular proliferation, apoptosis and differentiation in
many cell types [2].
Recent epidemiological studies have shown an associa-
tion between low serum 1,25D levels and increased risk of
breast, colorectal and prostate cancers. Furthermore, sev-
eral studies have reported a possible link between poly-
morphic variants in the vitamin D receptor gene and
increased susceptibility for primary and metastatic breast
cancer, squamous cell carcinoma, colorectal cancer and
prostate cancer [3-6]. Although the functional significance
of these polymorphic variants remains unknown, there is
strong evidence suggesting that they may have functional
consequences in epithelial carcinogenesis and tumour
progression [7,8]. VDR polymorphisms have been widely
studied in Caucasian populations in relation to breast
cancer (BC) [9-11] and malignant melanoma (MM) sus-
ceptibility [12,13], each finding different effects for SNPs,
depending on the population analyzed and environmen-
tal factors acting upon them.
It is of general interest to study the most characterised var-
iants in VDR in southern European countries, where sun
exposure is typically higher than in northern European
countries (maximum UV Index during the summer
months = 9 in Spain versus 6.5 in Netherlands) [14,15] In
this study, we investigated for the first time the role of pol-
ymorphisms in VDR in two epithelial cancers, sporadic
BC and MM, in the Spanish population. Additionally,
clinical and tumour phenotypic variables have been taken
into account to better define the involvement of VDR in
these pathologies.
Methods
Study Subjects, Data Collection and DNA Extraction
BC Study
The BC case-control study included a total of 549 consec-
utive and non-related sporadic BC cases and 556 control
women. Cases were recruited from 1st January 2002 to 31st
December 2006 from three Spanish public hospitals: 258
(47%) from Monte Naranco Hospital, in Oviedo; 155
(28%) from the Fundación Jiménez Díaz, and 136 (25%)
from La Paz University Hospital, both in Madrid. Con-
trols were unaffected Spanish women, recruited at three
centres in Madrid: 455 (82%) from the Menopause
Research Centre at the Instituto Palacios, 82 (15%) from
the Fundación Jiménez Díaz, and 19 (3%) from the
Madrid College of Lawyers. All cases and controls were
women and controls were selected so that their age range
was comparable to that of cases. We could not frequency
match due to the larger numbers of cases.
Information about personal characteristics of cases and
controls (age at diagnosis for cases or age at blood sample
collection for controls, age at menarche, parity and men-
opausal status), and clinical and tumour characteristics
for cases (metastasis at diagnosis, tumour grade, type and
size, nodal involvement, and immunohistochemical
markers), was either collected by the treating physician or
extracted by review of medical records. This information
is summarised in Additional file 1.
MM Study
The MM case-control study was based on 283 consecutive
and non-related sporadic MM cases that were recruited
from 1st  September 2004 to 15th  March 2008, at the
Departments of Dermatology of three hospitals in
Madrid: 147 (52%) from Gregorio Marañón General Uni-
versity Hospital, 54 (19%) from La Paz University Hospi-
tal and 82 (29%) from Ramón y Cajal University
Hospital. A total of 245 cancer-free controls, frequency
matched to cases by sex and age in ten-year categories,
were recruited from the Madrid College of Lawyers (218
participants, 89%) and from Gregorio Marañón General
University Hospital (27 participants, 11%).
A standardised questionnaire was used to collect informa-
tion on pigmentation characteristics (eye colour, hair col-
our, skin colour, number of nevi, presence of solar
lentigines), the presence of childhood sunburns, Fitz-
patrick's classification of skin type, tumour location, Bres-
low index (deep index), and personal and family history
of cancer, as described previously [16,17] (see Additional
file 2). Fitzpatrick's classification of skin type was assessed
for cases only, by review of medical records.
All participants in both studies were Caucasian and of
Spanish origin. All subjects gave informed consent and
the BC and MM studies were approved by the Ethics Com-
mittees of La Paz University Hospital and Gregorio
Marañón General University Hospital, respectively.
Genomic DNA from cases and controls was extracted using
the MagNA Pure LC Instrument according to the manufac-
turer's protocol as previously described [16,18,19].
SNP selection
Three public databases were used to collect information
about SNPs in VDR: NCBI http://www.ncbi.nlm.nih.gov,BMC Cancer 2008, 8:385 http://www.biomedcentral.com/1471-2407/8/385
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Ensembl http://www.ensembl.org, and HapMap http://
www.hapmap.org. Four SNPs were considered for inclu-
sion because they have been widely analysed in previous
epidemiological studies. All had minor allele frequency
(MAF) greater than or equal to 10%. Two are located on
exons, one is in the putative promoter region and the
other in the 3'utr region. The two coding SNPs selected
have been reported to be associated with breast cancer, in
previous studies [11,20,21].
Genotyping assays
Genotyping was carried out using the TaqMan platform
following the manufacturer's instructions. SNPs assays
were designed using Applied Biosystems Assay-by-Design
and Assay-on-Demand probes (Applied Biosystems, Fos-
ter City, CA, USA) (provided upon request). The genotype
of each sample was automatically determined by measur-
ing final allele-specific fluorescence in the ABI Prism
7900HT Detection System, using the SDS 2.1 software for
allele discrimination (Applied Biosystems, Foster city,
USA).
As a quality control measure, we included at least 2 sam-
ple duplicates and 1 non-template sample per 96-well
plate. Genotypes were scored by two different personnel
in the laboratory. We obtained a concordance rate of
100% for all four SNPs studied.
Statistical Analysis
For all polymorphisms studied, Fisher's exact test was
used both to test for deviations from Hardy-Weinberg
equilibrium (HWE) among controls and to compare dif-
ferences in the MAF distributions between cases and con-
trols.
In order to assess associations between genotypes, haplo-
types and cancer risk, several analyses were performed.
Genotype-related odds ratios (ORs), their corresponding
95% confidence intervals (CIs) and associated p-values
were estimated via unconditional logistic regression. This
was done for each of heterozygotes and minor-allele
homozygotes relative to common-allele homozygotes, as
well as under an additive model, in the latter case estimat-
ing an effect per copy of the minor allele carried. Known
or suspected risk factors for BC (age, number of live births,
age at menarche, and menopause status) and MM (eye
colour, hair colour, skin colour, number of nevi, lentigi-
nes, and childhood sunburns) were evaluated for poten-
tial confounding effects by including them in multivariate
analyses.
Associations between VDR  polymorphisms genotyped
and various individual, clinical and tumour characteristics
were assessed via logistic regression in order to determine
their potential modifying effects on BC and MM risk. This
was done for cases and controls pooled for each variable.
Eye colour (blue/green versus brown), hair colour (blond/
red versus brown/black), skin colour (fair versus brown),
number of nevi (= 50 versus < 50), presence of lentigines
(yes versus no) and childhood sunburn (yes versus no)
were used as the outcome variables for MM.
Among BC cases only, the presence of metastastic disease
at diagnosis (yes versus no), tumour histology (invasive
versus in situ), tumour grade (grade > 1 versus grade 1),
tumour size (> 2 cm versus = 2 cm), nodal involvement
(yes versus no), estrogen receptor status (positive versus
negative) and progesterone receptor status (positive ver-
sus negative), were used in the analysis. For MM cases-
only analyses, the prior diagnosis of MM (yes versus no),
phototype (I/II versus III/IV), tumour location (head/
neck/trunk versus extremities) and tumour depth (T2/T3/
T4 versus T0/T1) were considered as the outcome varia-
bles.
SPSS v11.0 was used to carry out these analyses. All p-val-
ues were two-sided and those less than 0.05 were consid-
ered statistically significant
Results and Discussion
Associations of VDR rs731276 and rs2228570 
polymorphisms with cancer risk
Allelic frequencies for each SNP and the p-value for their
comparison between cases and controls are presented in
Table 1. We found no evidence of departure from Hardy-
Weinberg equilibrium for any of the four SNPs genotyped
(all p-values > 0.05). Results from univariate and multi-
variate genotype analysis are shown in Table 2.
We observed evidence of differences in minor allele fre-
quency (MAF) between BC cases and controls for the syn-
onymous change rs731236 (TaqI) (p = 0.028). The
estimated OR per minor allele (C) in this SNP was 0.84
(95%CI 0.71–0.99, p = 0.034). This per-allele OR esti-
mate was not substantially different in the multivariate
analysis adjusting for age, number of live births, age at
menarche, and menopause status (OR per allele = 0.85,
95% CI 0.69–1.03, p = 0.102). Regarding the SNP
rs2228570 (FokI) (Met1Thr, formerly known as
rs10735810), weak evidence of differences in MAF
between BC cases and controls was observed (p = 0.080).
The estimated OR per minor allele in this SNP was 1.17
(95%CI 0.98–1.40, p = 0.081), whereas the per-allele OR
estimated in the multivariate analysis adjusting for poten-
tial confounding factors was higher, and statistically sig-
nificant (OR per allele = 1.26, 95%CI 1.02–1.57, p =
0.036).
In general, previous studies have found no evidence of
association with BC for rs731236 (TaqI) and rs2228570BMC Cancer 2008, 8:385 http://www.biomedcentral.com/1471-2407/8/385
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(FokI) [9,11,22-27]. All of these studies had limited statis-
tical power to detect a moderate association. Population
stratification may be another explanation for the lack of
consistency in results. However, two studies with mar-
ginal statistically significant results for rs731236 (TaqI)
reported contradictory results [11,24], whereas studies
using larger sample sizes from Caucasian populations
have shown risk effect of rs2228570 (FokI) consistent with
that detected in the present study [20,21]. An association
with rs2228570 (FokI) was observed after adjustment for
established risk factors including those used in the present
study. This difference may be due to the tight relationship
between VDR protein function and the hormonal aspect
of BC aetiology such as menarche, parity and menopause
[28,29].
In the case of MM, we did not observe any evidence of
association with rs731236 (TaqI) (OR per allele = 1.08,
Table 1: Allelic frequencies comparison between cases and controls in the four SNPs tested, in both BC and MM pathologies
BREAST CANCER MELANOMA HapMap
Other 
names
SNP Nucleotide Cases 
(N = 549)
Controls 
(N = 556)
Cases 
(N = 283)
Controls 
(N = 245)
Caucasian
SNP ID Location Change* MAF MAF p-value++ MAF MAF p-value++ MAF
rs4516035 5' upstrem T > C 0.41 0.39 0.27 0.44 0.40 0.28 0.45
rs2228570 FokI. 
rs10735810
Met1Thr G > A 0.37 0.34 0.08 0.31 0.33 0.33 0.44
rs731236 TaqI Ile352 T > C 0.38 0.43 0.028 0.41 0.39 0.50 0.44
rs739837 BglI 3' utr T > G 0.46 0.46 0.90 0.47 0.50 0.74 0.43
MAF, Minor Allele Frequency.
Statistically significant results (p < 0.05) indicated in bold.
* Correspondence of nomenclature of SNP alleles are as following: the FokI alleles G and A correspond to F and f, respectively; the TaqI alleles T and C
correspond to T and t, respectively; and BglI alleles T and G correspond to B and b, respectively.
++p-value, difference of MAF between cases and controls.
Table 2: Genotype frequencies comparison between cases and controls in the four SNPs tested, in both BC and MM pathologies
BREAST CANCER MELANOMA
Statistical Genotype non-adjusted adjusted† non-adjusted adjusted‡
SNP ID model alleles OR* 
(95% CI)
p-value OR* 
(95% CI)
p-value OR* 
(95% CI)
p-value OR* 
(95% CI)
p-value
rs4516035 Codominant CT 1.20 
(0.92–1.56)
0.19 1.15 
(0.83–1.58)
0.40 1.08 
(0.73–1.60)
0.69 1.17 
(0.70–1.96)
0.54
CC 1.16 
(0.82–1.65)
0.41 0.97 
(0.63–1.49)
0.88 1.51 
(0.90–2.53)
0.12 1.79 
(0.91–3.53)
0.09
Per minor 
allele
C- 1.09 
(0.92–1.29)
0.30 1.01 
(0.82–1.25)
0.91 1.20 
(0.94–1.55)
0.15 1.31 
(0.94–1.81)
0.11
rs2228570 Codominant GA 1.14 
(0.88–1.47)
0.32 1.26 
(0.89–1.66)
0.22 1.09 
(0.75–1.57)
0.66 1.23 
(0.76–2.01)
0.40
AA 1.41 
(0.96–2.08)
0.08 1.65 
(1.02–2.65)
0.041 0.69 
(0.38–1.25)
0.22 1.23 
(0.55–2.73)
0.61
Per minor 
allele
A- 1.17 
(0.98–1.40)
0.08 1.26 
(1.02–1.57)
0.036 0.91 
(0.70–1.19)
0.49 1.15 
(0.81–1.64)
0.43
rs731236 Codominant CT 0.84 
(0.64–1.09)
0.19 0.82 
(0.59–1.13)
0.22 1.26 
(0.85–1.87)
0.25 1.06 
(0.63–1.78)
0.81
CC 0.70 
(0.50–0.98)
0.040 0.72 
(0.48–1.09)
0.13 1.09 
(0.64–1.84)
0.76 1.17 
(0.57–2.39)
0.66
Per minor 
allele
C- 0.84 
(0.71–0.99)
0.034 0.85 
(0.69–1.03)
0.10 1.08 
(0.84–1.40)
0.55 1.08 
(0.77–1.52)
0.66
rs739837 Codominant TG 0.96 
(0.72–1.27)
0.76 0.96 
(0.69–1.35)
0.83 0.89 
(0.59–1.36)
0.60 0.64 
(0.36–1.13)
0.12
GG 1.03 
(0.74–1.44)
0.86 1.30 
(0.87–1.96)
0.20 0.82 
(0.50–1.36)
0.45 0.69 
(0.35–1.38)
0.29
Per minor 
allele
G- 1.01 
(0.86–1.20)
0.87 1.13 
(0.92–1.38)
0.25 0.91 
(0.71–1.17)
0.45 0.83 
(0.59–1.16)
0.28
*OR: Odds Ratio estimated under codominant and log-additive models; CI: Confidence Interval.
†Adjusted for age at diagnosis, number of live births, age at menarche and menopause status.
‡Adjusted for eye colour, hair colour, skin colour, number of nevi, lentigines, and childhood sunburn.
Statistically significant results (p < 0.05) indicated in bold.BMC Cancer 2008, 8:385 http://www.biomedcentral.com/1471-2407/8/385
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95%CI = 0.84–1.40, p = 0.55) or rs2228570 (FokI) (OR
per allele = 0.91 95%CI = 0.70–1.19, p = 0.49). These
results are consistent with the findings of smaller sample
size studies [13,30,31] although other studies reported a
protective tendency of rs731236 (TaqI) [12,32]. Only two
studies reported an association of rs2228570 (FokI) and
MM risk in North-European populations, one of them
being a larger sample size study [12,32].
The rs731236 (TaqI) SNP is in linkage disequilibrium
with other polymorphisms in the 3' extreme of the gene in
Caucasian populations. Functional studies of these poly-
morphisms have evaluated their putative implication in
the regulation of transcription, translation or RNA
processing, but no consistent results were obtained [33].
However, functional studies of rs2228570 (FokI) have
suggested a loss of the reported VDR benefits induced by
the minor allele, due to its location in the first codon of
the protein (Met1Thr). That is, the minor A allele appears
to be associated with the use of an alternate start codon,
which triggers a longer and less potent transcriptional
activator protein form [7], which is consistent with it
being associated with increased risk of BC. We did not
observe evidence of association for any other SNP in BC
or MM.
Associations of VDR polymorphisms with personal, clinical 
and tumoral characteristics
We assessed whether VDR SNPs were associated with var-
ious clinical and phenotypic characteristics using cases
and controls combined. We tested for associations with
tumour characteristics among cases only for each disease.
Results are summarised in Table 3. The rare allele in the
non-synonymous SNP rs2228570 (TaqI) appeared to be
strongly associated with the absence of childhood sun-
burns (OR per allele = 0.65, 95% CI 0.49–0.86, p =
0.003), and this was maintained among controls only
(OR per allele = 0.63). There was also weak evidence that
it is associated with a prior diagnosis of MM in MM
patients (p = 0.060). We also observed marginally signifi-
cant associations for the 3'utr SNP rs739837 (BglI) with
fair skin colour (p = 0.048) and with Fitzpatrick's photo-
type I/II (0.070). Finally, the VDR  promoter SNP
rs4516035 was associated with tumours located in the
head-neck or trunk (p = 0.020). No other associations
were observed for BC or MM. Although we did not detect
a significant effect of VDR SNPs directly on MM, the asso-
ciations identified with MM phenotypic characteristics
suggest that VDR SNPs may modulate MM susceptibility.
Further considerations
The strength of our study is the ability to control for the
many established risk factors for BC and MM, although we
recognize that there was potential for misclassification of
phenotypic characteristics due to the subjective nature of
the phenotypic attributes considered. Controls partici-
pated on a volunteer basis which may have introduced
some selection bias. However, the fact that they were fre-
quency matched to cases on age and sex for melanoma
and that breast cancer controls were selected so that their
age range was comparable to that of cases and that the var-
iable of primary interest was genetic would have kept such
bias to a minimum. It should be noted that, the sample
size of both studies was relatively limited and so associa-
tions can not be ruled out for rs731236 (TaqI), and
rs2228570 (FokI), particularly in MM. The association of
rs731236 (TaqI) and BC, was not statistically significant
under a multivariate model. However, the estimated rela-
tive risk did not change substantially, indicating that the
increase in p-value was due to the reduced sample size
(with available covariate data), rather than due to con-
founding. Finally, conclusions are based on nominal p-
values at 5% statistical significance and therefore require
replication in independent studies.
Conclusion
BC and MM tumour pathologies may be influenced by the
effect of variation in vitamin D intake through diet and sun
exposure, together with VDR polymorphisms. Therefore, in
a sunny region such as Spain, the effect of VDR polymor-
phisms on cancer risk may be more apparent than in other
Caucasian populations. The results obtained in this study
add to the evidence for a role of VDR as an important medi-
ator in the development of cancer. We found evidence of
association with BC for the non-synonymous variant
rs2228570 (FokI), and for the synonymous SNP rs731236
(TaqI). These findings require replication in large samples
and the role of these variants needs to be clarified by func-
tional studies. We have also reported several associations
among VDR SNPs and phenotypic risk factors that influence
MM susceptibility, indicating their potential effect in disease
development. The characterization of these and other poly-
morphisms in the VDR gene may help to better understand
the aetiology and development of cancer, and to define risk
groups to better target prevention strategies.
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Table 3: Personal, clinical and tumoral phenotypic characteristics comparison from both BC and MM pathologies in the four SNPs 
tested
Tumour rs4516035 rs2228570 rs731236 rs739837
Type Characteristic OR* (95% CI) p-value OR* (95% CI) p-value OR* (95% CI) p-value OR* (95% CI) p-value
BREAST CANCER
Metastasis‡ 0.53 (0.25–1.11) 0.09 1.00 (0.51–1.96) 0.99 1.20 (0.63–2.27) 0.58 1.11 (0.57–2.17) 0.75
Tumor histology 
(Invasive)‡
0.87 (0.57–1.32) 0.51 0.83 (0.54–1.28) 0.40 1.10 (0.72–1.69) 0.66 0.75 (0.49–1.15) 0.19
Tumor grade 
(Grade > 1)‡
0.93 (0.67–1.30) 0.68 1.19 (0.84–1.68) 0.33 1.22 (0.87–1.70) 0.26 0.76 (0.54–1.05) 0.09
Tumor size (> 2 
cm)‡
1.02 (0.77–1.35) 0.92 0.98 (0.73–1.30) 0.88 1.14 (0.86–1.51) 0.37 0.81 (0.61–1.08) 0.15
Nodal 
involvement‡
0.93 (0.70–1.23) 0.61 0.95 (0.71–1.27) 0.72 0.94 (0.71–1.25) 0.69 1.09 (0.82–1.45) 0.54
ER positive‡ 0.96 (0.66–1.41) 0.85 1.24 (0.84–1.84) 0.28 1.31 (0.90–1.90) 0.16 1.02 (0.71–1.46) 0.91
PR positive‡ 0.92 (0.67–1.26) 0.60 1.12 (0.80–1.55) 0.51 0.91 (0.67–1.24) 0.56 1.12 (0.83–1.51) 0.48
MELANOMA
Light Eye 
Colour+
1.03 (0.79–1.34) 0.82 0.91 (0.69–1.21) 0.52 0.92 (0.70–1.21) 0.56 1.06 (0.81–1.39) 0.64
Blond/Red Hair 
Colour+
0.99 (0.71–1.40) 0.99 0.78 (0.55–1.13) 0.19 1.02 (0.73–1.44) 0.89 1.45 (0.89–1.74) 0.20
Fair Skin 
Colour+
0.97 (0.75–1.26) 0.83 1.08 (0.82–1.42) 0.57 0.86 (0.66–1.12) 0.25 1.31 
(1.00–1.70)
0.048
N° of Nevi = 
50+
0.97 (0.66–1.40) 0.85 1.00 (0.67–1.49) 0.99 1.06 (0.72–1.54) 0.77 1.34 (0.90–1.97) 0.15
Presence of 
Lentigines+
1.03 (0.79–1.34) 0.84 0.79 (0.59–1.05) 0.11 1.20 (0.91–1.58) 0.21 0.90 (0.69–1.18) 0.45
Presence of 
Childhood 
Sunburns+
1.12 (0.87–1.45) 0.39 0.65 
(0.49–0.86)
0.003 1.10 (0.84–1.43) 0.49 0.91 (0.70–1.19) 0.50
Other MM‡ 1.26 (0.52–3.03) 0.61 2.43 (0.95–6.19) 0.060 1.83 (0.73–4.56) 0.19 0.70 (0.26–1.85) 0.47
Fitzpatrick's 
photoype I/II‡
0.74 (0.51–1.09) 0.13 0.85 (0.63–1.46) 0.89 0.91 (0.62–1.34) 0.63 1.43 (0.97–2.12) 0.070
Tumor Location 
(Head/Neck/
Trunk)‡
1.54 
(1.08–2.20)
0.020 1.16 (0.79–1.72) 0.45 1.16 (0.81–1.65) 0.42 1.17 (0.82–1.67) 0.38
Breslow Index 
(T2/T3/T4)‡
1.04 (0.72–1.51) 0.82 1.20 (0.80–1.79) 0.38 0.84 (0.57–1.24) 0.38 1.01 (0.69–1.47) 0.96
*OR: Odds Ratio per minor allele; CI: Confidence Interval, unadjusted p-values.
+Cases and controls pooled for each variable.
‡Cases only considered.
Statistically significant results (p < 0.05) indicated in bold.BMC Cancer 2008, 8:385 http://www.biomedcentral.com/1471-2407/8/385
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